[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"ire\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:ire":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,42,59],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":28,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":41},"100654476","ire-after-targeted-immunotherapy-in-hcc-with-portal-vein-tumor-thrombus-100654476",false,"NCT07799922","IRE After Targeted Immunotherapy in HCC With Portal Vein Tumor Thrombus","A Prospective, Randomized Controlled Phase II Clinical Study of Sequential or Non-sequential Irreversible Electroporation After Targeted Immunotherapy Induction in Patients With Unresectable Hepatocellular Carcinoma With Portal Vein Tumor Thrombus","Inclusion Criteria:\n\n* Age 18-75 years, any sex\n* Imaging-confirmed or histologically confirmed primary liver cancer\u002Fhepatocellular carcinoma (HCC)\n* After three cycles of target-immunotherapy induction, MDT review determines unresectable disease or inability to tolerate surgical resection\n* Willingness to receive standard conversion treatment\n* No prior palliative targeted immunotherapy or other systemic antitumor therapy\n* Maximum tumor diameter \\\u003C=5 cm and number of tumors \\\u003C=5\n* No extrahepatic metastasis; portal vein tumor thrombus Vp1-3\n* At least one measurable lesion according to RECIST 1.1\n* Adequate organ and marrow function: hemoglobin \\>=9.0 g\u002FdL; neutrophils \\>=1.5 x 10\\^9\u002FL; platelets \\>=100 x 10\\^9\u002FL; TBIL \\\u003C=3 x ULN; AST and ALT \\\u003C=5.0 x ULN; serum creatinine \\\u003C=1.5 x ULN or CrCl \\>60 mL\u002Fmin by Cockcroft-Gault formula\n* ECOG Performance Status 0-1\n* Expected survival of at least 3 months\n* Patients of childbearing potential and their partners agree to use contraception\n* Voluntary written informed consent\n\nExclusion Criteria:\n\n* Refusal to receive systemic therapy or possible surgery\n* Metastasis to other sites, such as lymph nodes, peritoneum, lung, bone, or brain\n* History of other malignancies, except cured basal cell carcinoma of the skin or cervical carcinoma in situ\n* Severe uncontrolled comorbidities, including uncontrolled congestive heart failure (NYHA III\u002FIV), unstable angina, poorly controlled arrhythmia, uncontrolled hypertension, active infection, uncontrolled diabetes, uncontrolled pleural effusion\u002Fpericardial effusion\u002Fascites requiring drainage, severe portal hypertension or portal cavernoma on imaging, gastric outlet obstruction, or respiratory insufficiency requiring oxygen\n* Major surgery within 30 days before screening\n* EGFR monoclonal antibody or EGFR-TKI within 30 days before screening\n* Allergy to any drug or component used in this protocol\n* Known or self-reported HIV infection or chronic hepatitis B or hepatitis C\n* Unresolved toxicity \\>=CTCAE grade 2 from prior treatment, except anemia, alopecia, skin pigmentation, or chemotherapy-induced neurotoxicity\n* Any other reason judged by the investigator to make participation inappropriate","ALL","18 Years","75 Years",{"count":20,"type":21},60,"ESTIMATED","INTERVENTIONAL",[24],"NA","This is a prospective, randomized, controlled, exploratory Phase II clinical study. Approximately 60 eligible patients with hepatocellular carcinoma and portal vein tumor thrombus who have received three cycles of target-immunotherapy induction and have non-progressive disease will be enrolled. All patients must be considered unresectable or unable to tolerate surgical resection by MDT review and must provide written informed consent. Participants will be randomized 2:1. Forty patients will undergo open or percutaneous IRE followed by continuation of the original target-immunotherapy regimen; twenty patients will continue the original treatment regimen alone. OS, PFS, tumor response, QoL, safety, and postoperative outcomes will be observed.",[27],"IRE",[27],"RECRUITING","2026-08-28",{"date":32,"type":33},"2026-09-02","ACTUAL",{"date":35,"type":33},"2026-05-20",{"date":37,"type":21},"2028-12-31",{"name":39,"class":40},"Tianjin Medical University Cancer Institute and Hospital","OTHER",1,{"id":43,"slug":44,"hasResults":11,"nctId":45,"briefTitle":46,"officialTitle":47,"acronym":4,"eligibilityCriteria":48,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":49,"targetDuration":4,"studyType":22,"phases":50,"briefSummary":51,"conditions":52,"keywords":53,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":54,"startDateStruct":55,"completionDateStruct":56,"leadSponsor":58,"locationsCount":41},"100654423","ire-after-chemotherapy-for-locally-advanced-pancreatic-cancer-100654423","NCT07799935","IRE After Chemotherapy for Locally Advanced Pancreatic Cancer","A Prospective, Randomized Controlled Phase II Clinical Study on Sequential or Non-Sequential Irreversible Electroporation Ablation After Chemotherapy Induction in Patients With Locally Advanced Unresectable Pancreatic Cancer","Inclusion Criteria:\n\n* Age 18-75 years, any sex.\n\nPrimary tumor biopsy confirms pancreatic adenocarcinoma.\n\nNon-progressive disease (PR or SD) after three cycles of chemotherapy induction.\n\nLocally advanced pancreatic cancer with \\>180-degree involvement of major vessels (celiac axis, superior mesenteric artery, superior mesenteric vein, or portal vein), confirmed unresectable by MDT review.\n\nNo prior palliative chemotherapy (except neoadjuvant\u002Fadjuvant chemotherapy discontinued \\>6 months); no other systemic antitumor therapy.\n\nAt least one measurable lesion per RECIST 1.1.\n\nAdequate organ and marrow function: hemoglobin ≥9.0 g\u002FdL; neutrophils ≥1.5×10⁹\u002FL; platelets ≥100×10⁹\u002FL; TBIL ≤3×ULN; AST and ALT ≤5.0×ULN; serum creatinine ≤1.5×ULN or CrCl \\>60 mL\u002Fmin.\n\nECOG Performance Status 0-1.\n\nExpected survival ≥3 months.\n\nPatients of childbearing potential and partners agree to use contraception.\n\nVoluntary written informed consent.\n\nExclusion Criteria:\n\n* Refusal to receive systemic chemotherapy or possible surgery.\n\nMetastasis to other sites (liver, peritoneum, lung, bone, brain).\n\nHistory of other malignancies (except cured basal cell carcinoma or cervical carcinoma in situ).\n\nSevere uncontrolled comorbidities (NYHA III\u002FIV heart failure, unstable angina, uncontrolled arrhythmia\u002Fhypertension, active infection, uncontrolled diabetes, uncontrolled effusions\u002Fascites requiring drainage, severe portal hypertension\u002Fcavernoma, gastric outlet obstruction, respiratory insufficiency requiring oxygen).\n\nMajor surgery within 30 days before screening.\n\nEGFR monoclonal antibody within 30 days before screening.\n\nAllergy to any drug or component used in this protocol.\n\nKnown HIV infection or chronic hepatitis B\u002FC.\n\nUnresolved toxicity ≥CTCAE grade 2 from prior treatment (except anemia, alopecia, skin pigmentation, chemotherapy-induced neurotoxicity).\n\nAny other reason judged by the investigator to make participation inappropriate.",{"count":20,"type":21},[24],"This is a prospective, randomized, controlled, exploratory Phase II clinical study. Approximately 60 eligible patients with locally advanced pancreatic cancer who have received three cycles of chemotherapy induction and have non-progressive disease will be enrolled. All patients must be considered unresectable by MDT review and must provide written informed consent. Participants will be randomized 2:1. Forty patients will undergo open IRE followed by continuation of the original chemotherapy regimen; twenty patients will continue the original treatment regimen alone. OS, PFS, tumor response, QoL, safety, and postoperative outcomes will be observed.",[27],[27],{"date":32,"type":33},{"date":35,"type":33},{"date":57,"type":21},"2027-12-31",{"name":39,"class":40},{"id":60,"slug":61,"hasResults":11,"nctId":62,"briefTitle":63,"officialTitle":64,"acronym":4,"eligibilityCriteria":65,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":66,"targetDuration":4,"studyType":22,"phases":67,"briefSummary":68,"conditions":69,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":70,"lastUpdatePostDateStruct":71,"startDateStruct":73,"completionDateStruct":75,"leadSponsor":76,"locationsCount":41},"100653996","hccanano-hope1-ire-after-chemotherapy-for-locally-advanced-unresectable-perihilar-cholangiocarcinoma-100653996","NCT07795619","HCCANANO-HOPE1: IRE After Chemotherapy for Locally Advanced Unresectable Perihilar Cholangiocarcinoma","A Prospective, Randomized Controlled Phase II Clinical Study of Sequential or Non-sequential Irreversible Electroporation After Chemotherapy Induction in Patients With Locally Advanced Unresectable Perihilar Cholangiocarcinoma","Inclusion Criteria:\n\n\\- Age 18-75 years, both sexes\n\nHistologically or cytologically confirmed locally advanced perihilar cholangiocarcinoma (Bismuth-Corlette type III\u002FIV or equivalent)\n\nNon-progressive disease (PR or SD) after 3 cycles of standard induction chemotherapy\n\nMDT-confirmed unresectable disease after induction therapy\n\nNo prior palliative systemic therapy\n\nAt least one measurable lesion per RECIST 1.1\n\nECOG Performance Status 0-1\n\nAdequate organ and marrow function: Hb ≥9.0 g\u002FdL, ANC ≥1.5×10⁹\u002FL, platelets ≥100×10⁹\u002FL, TBIL ≤3×ULN, AST\u002FALT ≤5×ULN, serum creatinine ≤1.5×ULN or CrCl \\>60 mL\u002Fmin\n\nLife expectancy ≥3 months\n\nWilling to use contraception if of childbearing potential\n\nWritten informed consent\n\nExclusion Criteria:\n\n\\- Refusal to receive systemic chemotherapy or possible surgery\n\nMetastasis to liver, peritoneum, lung, bone, brain, or other distant sites\n\nHistory of other malignancies (except cured basal cell carcinoma or cervical carcinoma in situ)\n\nSevere uncontrolled comorbidities (e.g., NYHA III\u002FIV heart failure, unstable angina, uncontrolled arrhythmia, uncontrolled hypertension, active infection, uncontrolled diabetes, significant effusions, severe portal hypertension, gastric outlet obstruction, respiratory insufficiency)\n\nMajor surgery within 30 days before screening\n\nEGFR monoclonal antibody or EGFR-TKI within 30 days before screening\n\nAllergy to any protocol-related drug or component\n\nKnown HIV infection or chronic hepatitis B\u002FC (active)\n\nUnresolved toxicity ≥CTCAE grade 2 from prior treatment (except anaemia, alopecia, skin pigmentation, or chemotherapy-induced neuropathy)\n\nAny condition judged by the investigator to make participation inappropriate",{"count":20,"type":21},[24],"Irreversible electroporation is a non-thermal ablative technology that uses high-voltage electric pulses to create permanent nanopores in tumor cell membranes, leading to apoptosis or other forms of cell death. Because the mechanism is primarily non-thermal, IRE may better preserve extracellular matrix, bile ducts, vessels, and other critical structures than thermal ablation, which is relevant for tumors adjacent to major vascular or biliary anatomy.\n\nThe main anticipated clinical value of IRE in these protocols is local disease control and potential survival benefit when used after induction therapy in patients with non-progressive disease. The procedure may be performed by open or percutaneous access according to tumor location, safety considerations, and institutional expertise. Perioperative management, imaging guidance, and post-procedure monitoring will follow institutional standards.\n\nPost-IRE gastrointestinal dysfunction may occur. Symptom-directed supportive care, including electroacupuncture where appropriate and approved by the investigator, may be used as supportive management. Such care is not intended to replace oncologic treatment and will be recorded as concomitant treatment when administered.",[27],"2026-08-26",{"date":72,"type":33},"2026-08-31",{"date":74,"type":33},"2026-04-01",{"date":57,"type":21},{"name":39,"class":40}]